LifestyleHealthAIIMS study finds Chloroquine Nasal drops can potentially bar...

AIIMS study finds Chloroquine Nasal drops can potentially bar Covid-19 in early-stage

-

New Delhi (India): A study by the doctors of All India Institute of Medical Sciences (AIIMS), New Delhi reveals that Chloroquine (CQN), when administered as nasal drops, has the potential to prevent COVID-19 infection if administered before the infection is established.

The aim of the study was to explore the safety and efficacy of topical nasal administration of CQN drops in reducing viral load and preventing clinical progression in early COVID-19 infection.

“The present study suggests the potential of topical nasal CQN in the prevention of COVID-19 infection if administered before the infection is established. No significant differences in clinical or virological outcome were, however, demonstrated in patients with mild but established illness,” said Dr. Alok Thakar, professor at the departments of Otorhinolaryngology, Head & Neck Surgery at AIIMS.

The study was an exploratory, randomized controlled trial comparing topical administration of CQN drops in the nose with standard symptomatic management in patients with asymptomatic/mild COVID-19.

The study received institutional bio-safety clearance and ethical approval and was registered with the Clinical Trial Registry of India.

The study was conducted at a designated COVID-19 treatment facility (NCI-Jhajjar Campus) at the AIIMS. Study recruitment was from April 23 to May 6, 2020, with a sample size of 60 participants, and informed written consent was obtained from all participants.

“RT-PCR tests confirmed asymptomatic patients or those with mild COVID-19 illness were included in the trial. Patients were randomized in a 1:1 manner. Control arm (standard supportive treatment, n=30) was compared with intervention arm (n=30) of a standard treatment plus CQN eye drops (0.03 percent) repurposed as nasal drops administered six times daily (0.5 ml/dose) for 10 days,” noted the study, which is now published in the latest issue of Indian Journal of Medical Science.

The findings stated: “Intranasal CQN (0.03 percent) was noted as safe and well-tolerated. The clinical outcomes were uniformly good in the subset of patients with mild/ asymptomatic infection.

The good clinical outcomes in the control group indicated that a large sample size would be required to demonstrate the effectiveness of any intervention in mild COVID-19 on the basis of clinical outcomes alone.”

The present trial did not show any in vivo antiviral efficacy of intranasal CQN drops in patients with mild but established illness, it said. 

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

Swiss unanimously votes for same-sex union referendum

GENEVA — In Switzerland, a controversial same-sex marriage referendum has been resoundingly approved by voters of the conservative, rich Alpine...

New Covid surge overwhelms hospitals in parts of US

WASHINGTON, D.C. — According to one of the country's top health officials, the spike in coronavirus cases in the...

China wants effeminate male celebs to man up

WASHINGTON — Macho men are in and effeminate male performers are out as Beijing expands its crackdown on China's entertainment...

Billie Eilish, BTS to perform at climate change concert

Billie Eilish, BTS, and Elton John, among others, will donate their star power to Global Citizen Live on Saturday...

Google faces off EU in court over record $5.1 billion antitrust fine

This week, Google will face the European Commission in a five-day court hearing, appealing a record $5.1 billion fine...

WHO’s Covax misses 2021 target. What went wrong?

The latest supply forecast for Covax – the programme for sharing COVID-19 vaccines around the world – suggests that accelerating vaccination...

Must read

You might also likeRELATED
Recommended to you